AtaiBeckley
ATAI
7.35
0.00
0.00%
AtaiBeckley
US · ATAI
#2575 by market cap
Listed 2021
7.35
0.00
0.00%
Live - 5344 symbols - heartbeat 120s ago
· 2026-10-07 19:54
- Market cap
- 2.73B
- P/E (TTM)i
- -2.63
- P/Bi
- 15.44
- EPSi
- -2.91
- Div yieldi
- 0.00%
- 52W posi
- 98%
Reader sentiment
Are you bullish or bearish on ATAI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 16.39, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +1,227.60% YoY
Margins
- Operating margin
- -2,772.00%
- Net margin
- -16,142.02%
Key ratios & quality
- Altman Z-Scorei
- 16.39
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | 0 | 20.38M | 233.00K | 314.00K | 308.00K | 4.09M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.09M | 80.73M | 92.75M | 70.35M | 63.58M | 47.54M | 65.09M |
| Research & development | 3.08M | 11.41M | 47.96M | 74.31M | 62.20M | 55.46M | 53.06M |
| Operating profit | -8.17M | -92.14M | -120.33M | -144.43M | -123.03M | -102.17M | -113.35M |
| Pretax profit | -17.47M | -101.81M | -136.60M | -135.18M | -39.29M | -148.41M | -659.85M |
| Tax | 2.00K | 305.00K | -3.99M | 6.23M | 1.02M | -356.00K | 298.00K |
| Net profit | -24.38M | -178.63M | -174.24M | -157.42M | -43.90M | -150.05M | -660.15M |
| Basic EPS | 0 | -1 | -1 | -1 | 0 | -1 | -3 |
| Diluted EPS | -0.09 | -1.11 | -1.21 | -0.98 | -0.25 | -0.93 | -2.91 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.56M | 719.00K | 749.00K | 1.07M | 954.00K | 1.70M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 10.60M | 14.90M | 14.51M | 25.09M | 14.44M | 17.77M |
| Research & development | 11.33M | 11.09M | 14.68M | 15.96M | 17.41M | 28.07M |
| Operating profit | -20.34M | -25.25M | -28.41M | -39.35M | -30.16M | -41.72M |
| Pretax profit | -26.31M | -27.65M | -60.97M | -544.92M | -29.78M | -32.48M |
| Tax | 156.00K | 93.00K | 131.00K | -82.00K | 20.00K | 64.00K |
| Net profit | -26.47M | -27.75M | -61.10M | -544.84M | -29.80M | -32.55M |
| Basic EPS | 0 | 0 | 0 | -2 | 0 | 0 |
| Diluted EPS | -0.15 | -0.14 | -0.28 | -1.73 | -0.08 | -0.09 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 39.15M | 99.55M | 375.08M | 287.15M | 185.59M | 80.13M | 275.68M |
| Cash & ST investments | 30.06M | 97.25M | 362.27M | 273.11M | 179.26M | 62.33M | 256.04M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 62.12M | 111.55M | 414.17M | 305.44M | 293.48M | 159.39M | 292.72M |
| Total current liabilities | 1.61M | 12.30M | 20.94M | 19.90M | 20.12M | 24.95M | 23.48M |
| Short-term debt | -- | -- | -- | 180.00K | 275.00K | 9.84M | 271.00K |
| Long-term debt | 157.00K | 2.18M | 743.00K | 15.12M | 17.88M | 14.13M | -- |
| Total liabilities | 2,478,000.00 | 16,180,000.00 | 28,207,000.00 | 39,675,000.00 | 49,162,000.00 | 42,833,000.00 | 70,722,000.00 |
| Total equity | 59.64M | 95.37M | 385.96M | 265.77M | 244.32M | 116.55M | 222.00M |
| Retained earnings | -20.15M | -190.00M | -357.80M | -510.19M | -550.94M | -700.21M | -1.36B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 115.98M | 102.68M | 130.67M | 275.68M | 250.07M | 244.75M |
| Cash & ST investments | 98.20M | 95.94M | 114.61M | 256.04M | 230.77M | 225.81M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 195.78M | 189.20M | 239.82M | 292.72M | 264.88M | 264.79M |
| Total current liabilities | 28.50M | 25.55M | 16.54M | 23.48M | 24.96M | 28.53M |
| Short-term debt | 14.78M | 6.60M | 532.00K | 271.00K | 310.00K | 314.00K |
| Long-term debt | 9.30M | -- | -- | -- | -- | -- |
| Total liabilities | 43,509,000.00 | 45,279,000.00 | 79,912,000.00 | 70,722,000.00 | 66,098,000.00 | 88,356,000.00 |
| Total equity | 152.27M | 143.93M | 159.91M | 222.00M | 198.78M | 176.44M |
| Retained earnings | -726.64M | -754.37M | -815.44M | -1.36B | -1.39B | -1.42B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -7.85M | -20.77M | -63.25M | -104.47M | -84.12M | -82.44M | -102.68M |
| Depreciation & amortization | 6.00K | 24.00K | 47.00K | 168.00K | 319.00K | 473.00K | 1.01M |
| Free cash flow | -7.87M | -20.83M | -64.37M | -105.49M | -84.71M | -82.53M | -113.54M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 42.68M | 82.44M | 409.88M | -- | -- | 0 | 251.49M |
| Ending cash balance | 30.06M | 97.25M | 362.27M | 190.61M | 45.03M | 27.51M | 85.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -17.84M | -14.09M | -23.26M | -47.48M | -21.09M | -35.27M |
| Depreciation & amortization | 216.00K | 227.00K | 233.00K | 336.00K | 167.00K | 215.00K |
| Free cash flow | -23.11M | -14.22M | -28.62M | -47.59M | -21.09M | -35.27M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 59.77M | 16.22M | 36.44M | 139.06M | 0 | 0 |
| Ending cash balance | 58.29M | 61.94M | 30.40M | 85.30M | 43.10M | 168.81M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -24.06 | -227.10 | -71.75 | -47.80 | -15.97 | -83.10 | -390.36 |
| ROA %i | -22.76 | -195.60 | -63.84 | -42.35 | -13.43 | -65.92 | -291.99 |
| ROIC %i | -24.03 | -223.68 | -71.39 | -46.77 | -14.71 | -72.90 | -361.86 |
| 5-year avg ROE %i | -- | -- | -- | -- | -77.34 | -89.14 | -121.80 |
| EBIT margin %i | -- | -- | -590.52 | -61,987.12 | -11,665.61 | -47,169.16 | -16,108.76 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 24.36 | 8.09 | 17.92 | 14.43 | 9.22 | 3.21 | 11.74 |
| Quick ratioi | 24.12 | 8.01 | 17.61 | 14.01 | 9.02 | 2.57 | 11.52 |
| Debt / assetsi | 0.25 | 1.95 | 0.18 | 5.02 | 6.52 | 15.50 | 0.71 |
| LT debt / equityi | 0.27 | 2.40 | 0.20 | 5.81 | 7.77 | 12.78 | 0.81 |
| Interest coveragei | -- | -- | -- | -- | -13.79 | -46.50 | -566.86 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -75.27 | 159.87 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -79.55 | -76.63 | -100.95 | -390.36 | -378.29 | -417.48 |
| ROA %i | -64.09 | -58.97 | -70.51 | -291.99 | -288.02 | -294.36 |
| ROIC %i | -69.33 | -68.90 | -92.35 | -361.86 | -350.06 | -403.93 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -7,820.50 | -5,054.53 | -5,036.35 | -16,108.76 | -19,009.75 | -14,940.83 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.07 | 4.02 | 7.90 | 11.74 | 10.02 | 8.58 |
| Quick ratioi | 3.50 | 3.81 | 7.60 | 11.52 | 9.83 | 8.29 |
| Debt / assetsi | 13.62 | 4.87 | 1.23 | 0.71 | 0.76 | 0.71 |
| LT debt / equityi | 7.82 | 1.82 | 1.52 | 0.81 | 0.85 | 0.89 |
| Interest coveragei | -43.66 | -40.24 | -71.83 | -566.86 | -2,530.76 | 334,077.00 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Global discovery, research, development, and commercialization of highly effective mental health100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.